1.8 billion varieties of the second over-reviewed North China pharmaceutical research and development investment of more than 20 million

　　Pharmaceutical Network November 19, North China Pharmaceuticals issued a notice that the company received the Approval of the State Drug Administration to issue cyclosporine softgel (25mg, 50mg) of the "drug supplementary application approval", the drug two specifications through a consistent evaluation the basic situation
cyclosporine softgels are immune inhibitors, mainly applicable to the prevention of rejection of allogeneic kidneys, liver, heart, bone marrow and other organs or tissue transplantation, but also to prevent and treat bone marrow transplantation occurred in transplant anti-host reaction (GVHD); Developed by NOVARTIS, the product was launched in Germany in 1994 under the name Sandimmune Neoral (Shinto Ming); China's public medical institutions terminal cyclosporine sales (units: 10,000 yuan) According to the data of The Internet, in 2018 in China's urban public , county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal cyclosporine sales of up to 1.8 billion yuan, of which, capsules accounted for nearly 90% At present, there are 11 have the product production approval, North China Pharmaceutical s (North China Pharmaceuticals) for the second domestic through the product consistency evaluation of the enterprise, before that, only Hangzhou China-U.S East China Pharmaceutical evaluation North China Pharmaceuticals said that the company's cyclosporine softgels (25mg, 50mg) through consistency evaluation, conducive to the future market ingressment of the product and market competition Up to now, the company's two specifications of the drug cumulative research and development investment of 24.3715 million yuan (unaudited) net white feather finishing source: listed company announcement, minet database